Please note that log in for BLAW products will be unavailable for scheduled maintenance on Sunday, February 5th from approximately 4 AM to 5 AM EST.
Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Pfizer, BioNTech Submit Initial Data for Shot in Young U.S. Kids

Sept. 28, 2021, 12:24 PM

Pfizer Inc. and partner BioNTech SE said they have submitted initial data to U.S. regulators about the use of their Covid-19 vaccine in children ages 5 to 11, one step closer to bringing shots to school-age kids.

The companies said in a statement that they expect to make a formal request for emergency authorization in the coming weeks. Submissions to regulators in Europe and elsewhere are also planned.

On Sept. 20, the companies said their vaccine was safe and had produced strong antibody responses in children ages 5 to 11 in a trial with 2,268 participants. Two doses in school-age ...